India’s pharma exports stay resilient amid global headwinds, near $29 billion mark

India’s pharmaceutical exports maintained steady momentum this financial year, nearing the $29 billion mark through February, even as global markets remained volatile.

K Raja Bhanu, Director General of the Pharmaceuticals Export Promotion Council of India (PHARMEXCIL), said the sector has continued to show resilience, registering moderate but consistent growth.

Also Read: Pharma calls in sick after Trump’s 100% tariff threat


"Inspite of global challenges, pharmaceuticals exports have been one of the few sectors that has maintained its growth momentum. Pharmaceutical exports during the period April-February FY26 stood at USD 28.29 billion, reflecting a growth of 5.6 per cent compared to the same period in FY25 led by formulations, biologicals, vaccines and Ayush products," he said.

India’s pharmaceutical industry, currently valued at around $60 billion, is expected to more than double in size to $130 billion by 2030, underlining strong long-term growth prospects.

Also Read: Indian pharma sector faces supply risk amid West Asia conflict despite duty waiver

Despite pricing pressures and trade uncertainties in global markets, export performance has remained robust. Shipments rose to $30.47 billion in FY 2024-25, marking a 9.4 per cent year-on-year increase.

The growth has been driven largely by high-value segments such as formulations, biologicals and vaccines, alongside increasing traction in Ayush products, helping India sustain its position as a key global supplier of affordable medicines.